# Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration

> **NCT01176903** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 65 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Glycopyrrolate
- **DRUG:** Tiotropium
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01176903
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2010-11
- **Final completion:** 2011-08
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01176903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01176903, "Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01176903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*